Physician profile
Debra J Stultz
NPI 1346249836
$173,475.23
in general payments reported to CMS, 2019-2025
30 companies · $60K in 2025
The $60K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,817 · 2020: $16K · 2021: $19K · 2022: $25K · 2023: $36K · 2024: $14K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Consulting Fee: $30K · Honoraria: $14K · Food and Beverage: $6,831 · Travel and Lodging: $2,494 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,650 · Education: $701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $53,959.00 |
| Consulting Fee | $30,148.00 |
| Honoraria | $14,025.00 |
| Food and Beverage | $6,831.23 |
| Travel and Lodging | $2,494.06 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,650.00 |
| Education | $700.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $77,693.14 | 2020-2025 | Wakix |
| Lilly USA, LLC | $35,159.39 | 2025 | Zepbound, Mounjaro |
| Axsome Therapeutics, INC. | $28,347.64 | 2022-2025 | Sunosi, Auvelity |
| Jazz Pharmaceuticals INC. | $23,723.23 | 2019-2025 | |
| Abbvie INC. | $2,693.80 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Teva Pharmaceuticals USA, INC. | $1,279.84 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $1,048.83 | 2019-2022 | |
| Alkermes, INC. | $615.87 | 2023-2025 | Lybalvi, Aristada, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $555.77 | 2020-2025 | Rexulti |
| Corium, LLC | $513.53 | 2022-2024 | Azstarys |
| Allergan, INC. | $381.88 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $291.87 | 2019-2025 | Spravato |
| Avadel Cns Pharmaceuticals, LLC | $148.82 | 2024-2025 | Lumryz |
| Takeda Pharmaceuticals U.S.A., INC. | $143.20 | 2020-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $128.70 | 2022-2025 | Ingrezza |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $121.91 | 2022-2025 | Caplyta |
| Eisai INC. | $103.54 | 2020-2021 | |
| Lundbeck LLC | $90.70 | 2019-2023 | Rexulti |
| Ironshore Pharmaceuticals INC. | $84.40 | 2019-2023 | Jornay Pm |
| Inspire Medical Systems, INC. | $80.20 | 2024 | Inspire |
| Vanda Pharmaceuticals INC. | $66.76 | 2019-2025 | Fanapt, Hetlioz |
| Biohaven Pharmaceutical Holding Company Ltd. | $53.67 | 2022 | |
| Supernus Pharmaceuticals, INC. | $39.68 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $20.06 | 2021 | |
| Pfizer INC. | $18.24 | 2023 | |
| Shire North American Group INC | $17.83 | 2019 | |
| Philips North America LLC | $13.99 | 2020 | |
| Neos Therapeutics, Lp | $13.87 | 2020 | |
| Tris Pharma INC | $13.19 | 2019 | |
| Impel Pharmaceuticals INC. | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Stultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.